Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + AI Followed by SHR-A1811 in HR+/HER2-Low Breast Cancer
NCT07618923Phase 2Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
01
Overview
A Phase 2 trial of dalpiciclib, trastuzumab rezetecan in breast cancer, sponsored by Tangdu Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
dalpiciclibtrastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07618923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07618923.